Calderón PEA, Castillo LIY, Govea CLH

Language: Spanish
References: 9
Page: 213-218
PDF size: 200.53 Kb.

ABSTRACT

Objective: To determine the prevalence of these symptoms in the Mexican population treated at the General Hospital no. 46 and to examine whether anosmia is related to a mild form of the disease.
Materiales and Methods: A descriptive cross-sectional study was carried out, extracting information from patients treated at the General Hospital no. 46 with a positive test for SARS-CoV-2, from June 2020 to September 2021.
Results: The sample included 8694 patients with a mean age of 49 years; 52.8% were men; 28.4% were classified as severe patients, with a predominance of males (p = 0.008). A prevalence of 10.6% of anosmia and 10.8% of dysgeusia was found. The relationship between the absence of anosmia and death as the cause of discharge was analyzed, considering sex a covariate. The results indicated that, in the case of men, the absence of anosmia was associated with a higher probability of death as a cause = 0.008). A prevalence of 10.6% of anosmia and 10.8% of dysgeusia was found. The relationship between the absence of anosmia and death as the cause of discharge was analyzed, considering sex a covariate. The results indicated that, in the case of men, the absence of anosmia was associated with a higher probability of death as a cause of hospital discharge.
Conclusions: This inverse association between anosmia and mortality could have important implications in the classification and management of patients. Therefore, it is essential to continue investigating this relationship through more multicenter studies.

REFERENCES

1. Dong E, Du H, Gardner L. An interactive web-based dashboardto track COVID-19 in real time. Lancet Infect Dis 2020; 20 (5): 533-4. http://dx.doi.org/10.1016/S1473-3099(20)30120-1.

2. Santos REA, da Silva MG, do Monte Silva MCB, BarbosaDAM, Gomes AL do V, Galindo LCM, et al. Onset and durationof symptoms of loss of smell/taste in patients withCOVID-19: A systematic review. Am J Otolaryngol 2021; 42(2). doi: 10.1016/j.amjoto.2020.102889.

3. Nef P. How we smell: The molecular and cellular bases ofolfaction. News Physiol Sci 1998; 13: 1-5. doi: 10.1152/physiologyonline.1998.13.1.1.

4. Parma V, Ohla K, Veldhuizen MG, Niv MY, Kelly CE, BakkeAJ, et al. More than smell – COVID-19 is associated withsevere impairment of smell, taste, and chemesthesis.Chem Senses 2020; 45 (7): 609-622. doi: 10.1093/chemse/bjaa041. XX(June):1–14.

5. Ortiz-Brizuela E, Villanueva-Reza M, González-Lara MF,Tamez-Torres KM, Román-Montes CM, Díaz-Mejía BA, etal. Clinical and epidemiological characteristics of patientsdiagnosed with COVID-19 in a tertiary care center in MexicoCity: A prospective cohort study. Rev Invest Clin 2020; 72(3): 165-77. doi: 10.24875/RIC.20000211.

6. Albarran-Sanchez A, Noyola-García ME, Calderón-Vallejo A,Guízar-García LA, Rosales-Dueñas F de J, Barrientos-FloresC de J, et al. [Neurological manifestations in patients withsevere COVID-19 in a tertiary care center]. Rev Med InstMex Seguro Soc 2021; 59 (6): 545-50.

7. Moein ST, Hashemian SMR, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarkerfor COVID-19. Int Forum Allergy Rhinol 2020; 10 (8): 944-50.doi: 10.1002/alr.22587.

8. Yan CH, Faraji F, Prajapati DP, Ostrander BT, DeCondeAS. Self-reported olfactory loss associates with outpatientclinical course in Covid-19. Int Forum AllergyRhinol 2020; 10 (7): 821-831. doi: 10.1002/alr.22592.

9. Cortés-Tellés A, López-Romero S, Mancilla-Ceballos R,Ortíz-Farías DL, Núñez-Caamal N, Figueroa-Hurtado E.Risk factors for mortality in hospitalized patients withCOVID-19: An overview in a Mexican population. TubercRespir Dis (Seoul) 2020; 83 (1): 546-54. doi: 10.4046/trd.2020.0095.